News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis completes acquisition of Canadian company Topigen Pharmaceuticals Inc
Pharmaxis Ltd announced today it has issued 3.2 million shares on completion of the acquisition of Canadian based private biopharmaceutical company Topigen Pharmaceuticals Inc.The agreement to purchase Topigen was announced to the market on 12 January 2010.
Read full media release - pdf
Pharmaxis completes clinical trial with the antifibrotic agent, PXS25
Pharmaxis today announced it had completed the first Phase I clinical trial in healthy volunteers with its new drug candidate, PXS25.
Read full media release - pdf
Pharmaxis to acquire Canadian company TOPIGEN Pharmaceuticals Inc.
Pharmaxis Ltd (ASX:PXS) announced today that it has signed an agreement to acquire Canadian based private biopharmaceutical company Topigen Pharmaceuticals Inc. in a transaction that will enhance the Pharmaxis respiratory drug development portfolio and complement the existing products and drugs under development.
Read full media release - pdf